ORGNAIZATION OF INTERNATIONAL CENTRE
Artificial cell was invented at McGill by Chang (Chang Chang Science 1964). Right from the beginningI realizes that this is such a large area that it will not be possible or ethical for one laboratory, one center, one university or even one country to do everything. As a physician researcher with the aim to do what is best for the patients, my plan has been to continue to do frontier innovative research of the future and at the same time to encourage others around the world to develop his ideas for patient use. This is by publishing all the reproducible details and methods; by encouraging and helping others to do this research; by sending researchers to help others to start research in this area; by organizing international network, international meetings, international journals, books and a public service website containing complementary papers, books and videos for free access by all www.artcell.mcgill.ca
ORGANIZATION CHART FOR THIS INTERNATIONAL EFFORT www.artcell.mcgill.ca/centrechart.pdf
1.
AT McGILL
Placed our emphasis on innovative ideas that depends on original ideas of individuals rather than extensive staff or facilities. This way, we have been more than competitive with the much larger international centers. Most of the original ideas in this area come from the director’s laboratory.
Associate members from McGill:
They come from departments of Physiology, Biomedical Engineering, Experimental Medicine, Medicine and Surgery. Others come from the departments of Bioengineering , Chemical Engineering and Mechanical Engineering and also McGill’s Biotechnology program .
Collaborate with other universities:
The director holds a number of non-salary voluntary positions as honorary professor of Nankai University, China; Honorary Professor of Peking Union Medical College of the Chinese Academy of Medical Sciences (CAMS), Honorary Professor and key consultant of the Blood Transfusion Institute of the Chinese Academy Medical Sciences; and honorary professor of the Shantou University Medical College in his hometown. In 2019 his hometown Shantou university formed the “Father of Artificial Cells: Chang Ming Swi Academia Specialist Research Station” for their newly built Clinical Research Centre building.
Some
examples of Chang helping other groups:
Way back in 1964, the late Harvard Professor Folkman of angiogenesis
fame phoned me for the detail procedure of my 1964 Science paper for his PhD
student, the now well-known Professor Robert Langer of MIT. For many years
Langer has interacted with me in organizing meetings and was a member of
editorial board of our journal
·
Connaught
Laboratory: I helped the director of Connaught start a research project on
artificial cells containing islet. His research associate there, Professor A Sun
did some excellent research.
·
The
late Professor Sam Sideman, Chair of Biomedical Engineering, Israel Institute
of Technology, Technion, has collaborated in hemoperfusion and blood
substitutes and coeditor with me 2 books.
·
Help
Professor Neufeld of McGill’s Chemical Engineering and his postdoc Dr Poncelet
start their research in this area. Prof Neufeld later become Chairman of
Chemical Engineering at Queens and works full time in this area. They have
organized annual meetings on Bioencapsulation, especially in Europe.
·
Help
Professor Mason of Chemistry at McGill and his postdoc Dr Kondo start a program
on AC
·
Help a
Professor in Polymer chemistry at McGill to start research on AC
·
Help
Professor Charles Scriver at McGill to start a research project on the use of
AC for PKU
·
Help
Dr Paul Barre establish the Hemoperfusion procedure in McGill teaching
hospital. He becomes the director of dialysis at McGill
·
Professor
C Yang, has collaborated in blood substitutes for many years – was director and
now emeritus director of the Blood Transfusion Institute of Peking Union
Medical College and Chinese Academy of Medical Sciences
·
In
1968, Muller and Rudin reported that they used the method from Chang Science
1964, to prepare lipid membrane artificial cells. I “brain washed” a McGill
Biochemistry PhD graduate, Gregoriadis, to study
lipid membrane artificial cell for drug delivery for his postdoc in England
with Bangham using their onion like multilaminar
lipid microspheres. This has resulted in
liposomes now used commonly for drug delivery.
·
D’Agnillo, (PhD with me in Physiology) to help Dr Alayash head of division of FDA/NIH to start a research
program on blood substitutes. (He is now a senior staff there)
·
BL Yu
(PhD with me in Biomed Eng) to help the late Dr. Zapol, Chief Anesthesiology, MGH Harvard start a research
program on blood substitute (She is now an assistant Professor there)
·
Keipert (PhD with me in Physiology) to help start the blood
substitute program for the late Professor Winslow at Letterman Institute and UC
San Diego, he then become VP of Winslow’s company on blood substitutes
·
Prakash
(PhD with me in Physiology) now professor at McGill Biomedical Engineering with
his companies.
·
Poznanski (My first PhD graduate, Physiology) is director
emeritus of Robert Research Institute.
·
Chawla,
Daka & Ning join as staff at Health Canada
Regulatory division.
·
Piskins both return to Turkey as professors.
·
YT Yu
helps to start a successful hemoperfusion company in China.
·
KF Gu
(PhD with me Chemical Enginering) helps Montreal IBEX
Co on recombinant enzyme production.
·
The
late Vivek Dixit (PhD with me in Physiology) professor and head of the
artificial liver unit at UCLA
·
Wang
(PhD with me in Expt Med) now associate Professor and
director of a program at the 3rd affiliated hospital of Beijing
University Medical School.
·
Bian (PhD with me in Biomedical Engineering and coinventor with me), is now
senior administrator of the 3rd Generation Blood Substitute Co, Proheme in China. CHEN Gang (postdoc with me) is their
manager. Jing (PhD with me in
Physiology) is their representative in Canada. Guo (PhD with me in Expt Medicine) and Gu (PhD with me in Chemical
Engineering) are their consultants.
·
others
include those from Saudi Arabia, Israel (Technion & Wiseman Institute),
Japan (Tabata )
and others.
2.
INTERNATIONAL NETWORK FOR ARTIFICIAL CELLS, BLOOD SUBSTITUTES &
BIOTECHNOLOGY
(ISABB) www.artcell.mcgill.ca/isabi.htm
Aims
This international
network was formed in 1976 to encourage research, development and clinical
applications in
artificial cells, blood substitutes, nanomedicine, regenerative medicine,
tissue
engineering, cell/stem
cell therapy, immunotherapy, hemoperfusion, bioencapsulation, and
related areas.
We have avoided a tight
and restrictive organizational structure. Instead, responsibilities are
widely distributed to
committees and organizers of congresses and symposia. This allows this
society to benefit from
fresh ideas and novel approaches and to move with the frontier of
research. This, plus
the enthusiastic participation and voluntary contribution of members of the
society, has allowed us
to continue this international network for more than 40 years without
charging membership
fees – this allows for world-wide participation with no restrictions related
to nationality, age,
experience, financial status. This also avoid any one group or groups from
controlling the network
or preventing it from moving in the frontier of research.
Officers
Elected Honorary
President & coordinator : T.M.S.Chang (McGill, Canada)
Elected executive
committee (Elected Past-Presidents of
ISABI congresses and/or symposia):
V.Bonamini (Italy)1978; L.Bulow (Sweden), 2015; C.U.Casciani(Italy)1990; T.M.S.Chang(Canada)1976,
1987,1991,1996, 2017 ; K. Kobayashi (Japan) 2003; R.Langer
(USA) 1994; Qin Liu (China) 2007; A. Mozzarelli (Italy)
2009;. Nikolaev(USSR) 1986; E.Piskin
(Turkey)1982,2001; H. Sakai (Japan) 2019, A.Trevino Becerra(Mexico)1985,
C.M.Yang(China), 1997, 2019; Zheng/Yang/Liu (China) 2013
Late Prof D. Falkenhagen (Austria); Late Prof. AG.Greenburg (USA) ;Late Prof M.Odaka
(Japan); Late
Prof S.Sideman(Israel); Late Prof E.Tsuchida (Japan); Late Prof R.Winslow
(USA)]: Late Professor
Y.T.Yu(China); Late Prof WM Zapol (USA) 2011
Subcommittee of ISABB:
International Committee on Blood Substitutes:ISBS
Elected executive board
members ISBS (past elected ISBS presidents or their
representatives):
1987: Chang (1987, 1991,1996, 2017)
1993: Keipert (for late
Winslow 1993, 1999)
1997: Yang/Yu YT (1997)
1997: Sakai (for late Tsuchida
1997)
2003: Kobayashi (2003)
2005: Greenberg (2005)
2007: Liu/Xiu (2007)
2009: Mozzarelli (2009)
2011: Zapol (2011)
2013: Zheng/Liu/Yang (2013)
2015: Leif Bülow (2015)
2017: Chang (2017)
2019: CM Yang, H Sakai (2019)
2023: Leif Bulow (2023)
Scientific Advisory Board
ISBS
Alayash
A, Abuchowski A. H Beumler,
Bian Y,Biro
B, Bucci E, Bülow L, Burhop
K, Chan G, Chang
TMS, Chen C, Cooper C, D’Agnillo F, Estep T, Feola M, Gould S, Han JQ, Hong Z, Intaglietta
M, Jahr S, Keipert P,Kim HW, Kluger R, Kobayashi K, Krafft
MP, Liu Q, Liu JX, Ma L, Meßmer K, Mozzarelli A, Palmer A, Privalle
C, Pugach I, Rausch C, Riess JG, Sakai H,
Simoni, Selivanov
E, Su ZG, Tsai AG, Wei G, Wong B,
Wong JT, Xiu RJ, Yang CM, Yu BL, Zafiris
G , Zal . Zapol W, ZhangY, Zhao L, Zhu YJW
Conferences
The emphasis is to concentrate on 1 or 2 areas that
need extensive effort towards routine clinical
uses. Once the area is in routine clinical use, the
area is left to other groups to look after and we then
concentrate on another 1 to 2 areas that needs major effort. Each congress or
symposium
president in consultation with his local organizing
committee, makes the final decision and has
the final responsibilities including financial
responsibilities. After each congress or symposium,
the president or appointed representative becomes a
member of the executive committee of the
ISABI.
1976 ISABI (I HPS) President: TMS Chang (McGill,
Canada)
1978 ISABI (II HPS) President: V Bonamini
(Bologna U, Italy) co-chair TMS Chang (McGill Canada)
1980 ISABI (III HPS) President: S. Sideman (Technion,
Israel) co-chair TMS Chang (McGill Canada)
1982 ISABI (IV HPS) President: E. Piskin
(Ankara U, Turkey) Honorary President: TMS Chang (Canada)
1983 ISABI (V HPS) President: C Z Huang (President,
Chinese Academy of Medical Sciences), co-chair TMS Chang (McGill Canada)
1985 ISABI (VI HPS) President: A. Trevino Becerra
(Mexico). Honorary President: TMS Chang (Canada)
1986 ISABI (VII HPS) President: V.Nikolaev(USSR Academy of Sci), Honorary President:TMS Chang
1987 ISABI (III ISBS) President: TMS Chang (McGill,
Canada), Cochair: R.Geyer (Harvard)
1987
1988 ISABI (VIII HPS) President: D.Falkenhagen & Klinkmann(Germany)
Honorary President:TMS Chang
1989 ISABI (VIV HPS)
1990 ISABI (X HPS): President: C.U.Casciani(Rome U, Italy), Cochiar:
G Splendiani (Rome U, Italy) Honorary President TMS
Chang (McGill, Canada)
1991 ISABI (IV ISBS) President: T.M.S.Chang(McGill, Canada) Cochair R.Geyer
(Harvard, USA)
1993 ISABI (V ISBS) President: R.Winslow(Letterman, USA) Cochairs: TMS Chang
(McGill, Canada) & R.Riess (France), 1993
1994 ISABI Congress President: R. Langer (MIT, U.S.A.),
Honorary president: TMS Chag (McGill)
1996 ISABI (VI ISBS) President: TMS Chang (McGill,
Canada) Cochairs: A.G.Greenberg
(Brown U, U.S.A) & E.Tsuchica (Waseda U, Japan)
1997 ISABI Congress President: Denian
Ba (President,Academy of Med
Sci, China) & C.M. Yang (CAMS, China), Honorary President TMS Chang
(McGill, Canada)
1997 ISABI (VII ISBS) President: E.Tsuchida (Waseda U,
Japan) Cochairs: S.Sekiguchi (Red Cross, Japan) &
TMS Chang (McGill, Canada)
1999 ISABI (VIII ISBS) President: R.Winslow (UC at San Diego, U.S.A.) Cochairs: TMS
Chang (McGill, Canada), M.Intaglietta(UC at San
Diego, U.S.A.) & E.Tsuchida (Waseda
U, Japan)
2001 ISABI Congress President: E. Piskin
(Ankara U, Turkey) Honorary President: TMSChang (McGill)
2003 ISABI (IX ISBS) President: K. Kobayashi (Keio U,
Japan), Cochair: E.Tsuchida
(Waseda U, Japan), Honorary President: TMS Chang
(McGill, Canada)
2005 ISABI (X ISBS) President: G. Greenberg (Brown U,
U.S.A.) HonoraryPresident: TMS Chang
2007 ISABI (XI ISBS) President: Q. Liu
(Vice-president, Chineswe Academyof
Medical Sci., China) Executive President: R Xiu
(Academy of Medical Sci, China), Honorary President: TMS Chang (McGill)
2009 ISABI (XII ISBS) President: A. Mozzarelli (University of Parma, Italy), Vice Presidents
Professor Enrico Bucci (University of Maryland) and Professor Clara Fronticelli ( Johns Hopkins
University, U.S.A.), Honorary
President: Professor TMS Chang (McGill University, Canada)
2011 ISABI (XIII ISBS) President: Professor W Zapol (Harvard Medical School, U.S.A.) Honorary President:
Professor TMS Chang (McGill )
2013 ISABI (XIV ISBS) President: Professor Zheng (BTI China),
Vice presidents Professor Liu (BTI China) & Professor Yang (BIT China),
Honorary President, Professor Chang (McGill, Canada)
2015 ISABI (XV ISBS) President: Professor L Bulow
(Lund, Sweden), Honorary President, Prof TMS Chang
2017 ISABI Congress (XVI ISBS, V ISNS) Professor TMS
Chang, 60th anniversary Congress on Artificial Cells in conjunction with XVI
ISBS and V ISNS (McGill, Canada)
2019 ISABI (XVII ISBS) China/Japan: Presidents Prof CM
Yang/Prof H Sakai; Honorary President: TMS Chang
2021(cancelled because of pandemic)
2023 ISABI (XVIII ISBS) President Prof Leif Bulow,
Lund. Sweden Honorary President: TMS Chang
2024 ISABI (XIX ISBS) Co-presidents: Prof J Jahr & Prof A Doctor (U.S.A.), Honorary President TMS
Chang (McGill,Canada)
3.
ARTIFICIAL CELLS, NANOMEDICINE AND BIOTECHNOLOGY, an international
journal
(http://www.tandfonline.com/action/showMostReadArticles?journalCode=ianb20
)
Publisher:
Frances & Taylor,
U.K.
This is a peer review
journal that is the oldest journal in the field having started in
1972 as "Biomaterial,
Medical Devices & Artificial Organs, an international journal".
1979: Chang became the
editor in chief and allows the name of the journal to change with time
to reflect the frontier
of research in the area. Before 2003 this journal was "Artificial Cells,
Blood Substitutes and
Immobilization Biotechnology").
2003: Starting in 2003
it was "Artificial Cells Blood Substitutes and Biotechnology.
2012 it became
Artificial Cells, Nanomedicine and Biotechnology. Its demand is such that in
2016 the publisher has
increased the issues from 6/year to 8/year with corresponding increase in
the total pages. In
2019 the submission increased to 2,400 that required too much time for the
editor in chief. He thus becomes emeritus editor to be free from day-to-day
functions and looking after major matters.
Editor in chief
1980-2020 Emeritus Editor 2020-
TMS Chang (McGill,
Canada);
Three coeditors in chief 2020-
D Misra (USA) W Chrzanowski
(Australia) P Roach (U.K.)
Associate Editors: S. Bruno (Italy), G. Budak (Turkey), G. Chan (China), Chen. G
(China), E. Georges
(Canada), S. Prakash
(Canada), H. Sakai (Japan), BL Yu (USA), JYW Zhu (China),
International Editorial
Board: 52 members
Please see home page: http://www.tandfonline.com/action/showMostReadArticles?journalCode=ianb20
for more details
4.BOOK
SERIES ON REGENERATIVE MEDICINE, ARTIFICIAL CELLS AND
NANOMEDICINE http://www.medicine.mcgill.ca/artcell/1%20book%20series.pdf
(World Science
Publisher/Imperial College Press)
Editor in chief: TMS Chang (McGill,Canada)
Volume 1: Monograph “ARTIFICIAL CELLS: Biotechnology, Nanomedicine,
Regenerative Medicine,
Blood Substitutes,
Bioencapsulation and Cell-Stem Cell Therapy” Chang 2007 454 pages with full
text
now available free on http://www.medicine.mcgill.ca/artcell/2007%20ebook%20artcell%20web.pdf
Volume 2: Present and future Therapies
for End-Stage Renal Failure. Editors: Eli Friedman & MC
Mallappallil (2010)
Volume 3: Selected Topics in Nanomedicine. Editor: TMS Chang (2013)
Volume 4: Hemoperfusion and plasma-perfusion: general, selective, immune and
leucocyte adsorbents.
Editors: TMS Chang, Y
Endo, VG Nikolaev, T Tani, YT Yu and WH Zheng (2017)
Volume 5: Nanobiotherapeutic Blood Substitutes:
Editor in chief: TMS Chang, Co-editors: Bulow, Jahr ,
Sakai and Yang 2021 Available free
online at: https://www.worldscientific.com/doi/epdf/10.1142/12054
Volume 6: TMS Chang: 3rd edition of Monograph “ARTIFICIAL CELLS” Chang for
2023:
5.WEBSITE
The Web Site of this
international
network: www.medicine.mcgill.ca/artcell or www.artcell.mcgill.ca or
www.artificialcell.info